Sovleplenib

索乐匹尼布

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameSovleplenib
Drug Alias Name醋酸索乐匹尼布HMPL-523 acetateHM-0523HMPL-523
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitors
TargetsSpleen tyrosine kinase
Therapy Area/IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicAnemia, Hemolytic, Autoimmune +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandNorway +[11] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesHutchison Medipharma Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHutchmed (Hong Kong) LtdHutchison Medipharma Ltd
Inactive CompaniesHutchison Huangpu Medicine (Suzhou) Co Ltd
Active IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicAnemia, Hemolytic, Autoimmune +[5] 
Inactive IndicationsArthritis, RheumatoidHematologic NeoplasmsLymphoma, Non-Hodgkin +[5] 

Other Information

ATC CodeN/A
Related LinksDrugBank